Svensk version All offices All contacts Home About Sobi Patients Research Partnering Healthcare Professionals Investors & Media Careers Products We are an integrated biotechnology company dedicated to rare diseases. Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases. Products Transparency Sobi supports transparency initiatives, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code in Europe and the Physician Payments Sunshine Act in the United States (Sunshine Act). Read more Annual General Meeting 2017 The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Thursday, May 4, 2017 at 3.00 p.m. at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden. Read more Sobi's report for the first quarter 2017 is published Q2 2017 report Q1 2017 report Annual report 2016 CEO comment on Q4 and FY 2016 results On-line version of the annual report 2016 Financial report archive Share Price More About the Share News Reports Show: All News Press releases Sobi receives approval from the FDA for once-daily dosing frequency of Orfadin® for the... 2017-09-05 13:00 in Press releases New number of shares and votes in Swedish Orphan Biovitrum AB 2017-08-31 08:00 in Press releases The board of directors exercises authorization for repurchase of shares to secure the c... 2017-07-19 08:15 in Press releases Sobi™ publishes its report for the second quarter 2017 2017-07-19 08:00 in Press releases More news Contact Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden Phone: +46 8 697 20 00 Reg.No. 556038-9321 © 2013 Swedish Orphan Biovitrum AB (publ) – All rights reserved Quick Links Terms of use Privacy policy All contacts Follow us Press releases News Financial reports

Svensk version All offices All contacts Home About Sobi Patients Research Partnering Healthcare Professionals Investors & Media Careers You are here: Start>Patients>Therapy Areas Patients Therapy Areas Haemophilia Inflammation Inherited Metabolic diseases Oncology Other Medical Contacts Patients Organisations Therapy Areas Amina living with urea cycle disorder Read more about our therapy areas Haemophilia Oncology Inflammation Other Inherited Metabolic diseases Updated 2013-03-25 Tip A Friend Print Contact Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden Phone: +46 8 697 20 00 Reg.No. 556038-9321 © 2013 Swedish Orphan Biovitrum AB (publ) – All rights reserved Quick Links Terms of use Privacy policy All contacts Follow us Press releases News Financial reports